Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Expert Opinion on Drug Safety Pub Date : 2025-02-01 Epub Date: 2024-12-09 DOI:10.1080/14740338.2024.2436062
Gábor Holló
{"title":"Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms.","authors":"Gábor Holló","doi":"10.1080/14740338.2024.2436062","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Adherence to therapy is fundamental for glaucoma management. Side effects of topical intraocular pressure (IOP)-lowering medications must be managed effectively to maintain adherence to the treatment plan and avoid disease progression. Ocular hyperemia is the most common side effect of topical IOP-lowering medications. It develops either as part of the mechanism of action of an IOP-lowering medication, usually requiring no medical intervention, or as a sign of allergy or toxicity, usually requiring intervention. Therefore, differentiating between types of ocular hyperemia is clinically important.</p><p><strong>Areas covered: </strong>This clinically oriented narrative review explains the various types of topical glaucoma medication-induced ocular hyperemia, describing the underlying causes, mechanisms of development, and areas involved. Five types of ocular hyperemia associated with IOP-lowering medications are described, relating to the effects of preservatives and active ingredients in mono- and combination therapies. Relevant studies were identified through targeted searches of PubMed and Google Scholar, conducted in August 2024.</p><p><strong>Expert opinion: </strong>Clinicians should identify the type and severity of ocular hyperemia related to IOP-lowering medications and, accordingly, remove allergenic or toxic agents from therapy. Patients should be advised to continue treatment if ocular hyperemia is mild, especially if it is an expected side effect of the medication.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"145-156"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2436062","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Adherence to therapy is fundamental for glaucoma management. Side effects of topical intraocular pressure (IOP)-lowering medications must be managed effectively to maintain adherence to the treatment plan and avoid disease progression. Ocular hyperemia is the most common side effect of topical IOP-lowering medications. It develops either as part of the mechanism of action of an IOP-lowering medication, usually requiring no medical intervention, or as a sign of allergy or toxicity, usually requiring intervention. Therefore, differentiating between types of ocular hyperemia is clinically important.

Areas covered: This clinically oriented narrative review explains the various types of topical glaucoma medication-induced ocular hyperemia, describing the underlying causes, mechanisms of development, and areas involved. Five types of ocular hyperemia associated with IOP-lowering medications are described, relating to the effects of preservatives and active ingredients in mono- and combination therapies. Relevant studies were identified through targeted searches of PubMed and Google Scholar, conducted in August 2024.

Expert opinion: Clinicians should identify the type and severity of ocular hyperemia related to IOP-lowering medications and, accordingly, remove allergenic or toxic agents from therapy. Patients should be advised to continue treatment if ocular hyperemia is mild, especially if it is an expected side effect of the medication.

与局部青光眼药物相关的眼部充血:理解和区分临床表现和潜在机制。
坚持治疗是青光眼治疗的基础。局部眼压(IOP)降低药物的副作用必须有效管理,以保持对治疗计划的依从性并避免疾病进展。眼部充血是局部降眼压药物最常见的副作用。它要么作为降低眼压药物作用机制的一部分而发展,通常不需要医疗干预,要么作为过敏或毒性的迹象而发展,通常需要干预。因此,鉴别眼部充血的类型在临床上具有重要意义。涵盖领域:这篇以临床为导向的叙述性综述解释了各种类型的局部青光眼药物引起的眼部充血,描述了潜在的原因、发展机制和涉及的领域。本文描述了与降低眼压药物相关的五种类型的眼部充血,这些充血与单一和联合治疗中防腐剂和活性成分的作用有关。通过2024年8月对PubMed和谷歌Scholar进行针对性搜索,确定相关研究。专家意见:临床医生应确定与降眼压药物相关的眼部充血的类型和严重程度,并相应地从治疗中去除致敏或毒性药物。如果眼部充血是轻微的,应建议患者继续治疗,特别是如果这是药物的预期副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信